for reducing thrombotic risk and fatigue in Jflare patients. Further studies are needed to address this issue.

### P4: Antiphospholipid Syndrome in Patients with Acute Myocardial Infarction

**Background** Antiphospholipid Syndrome (APS) is a known cause of thrombotic disorders, including Acute Myocardial Infarction (AMI). Although its incidence in AMI patients is not known, it may be an important factor in precipitating infarction, especially in younger adults.

**Methods** This is a case-control study consisting in 73 patients with Acute Myocardial Infarction, hospitalized at Cardiovascular Reanimation Clinic from 10 December 2015 - 10 October 2019. All patients included in the study were from 23 to 50 years old. In the case-group were included 24 patients with Antiphospholipid Syndrome and Acute Myocardial Infarction, and 49 patients were included in the control group, which consisted only in patients with AMI, with no presence of APS. In every patient were gathered data such as complete blood count + ESR, Antinuclear Antibodies (ANA), Anti-cardiolipin antibodies (ACA), C3 and C4 complement fraction, Anti-ds-DNA, CRP and Ejection Fraction (EF) in echocardiography. Female patients were asked about their abortion history. As recommended in the guidelines, in positive results for APS, ACA levels were repeated after 12 weeks in order to establish the diagnosis. All data were gathered and statistically analyzed using Excel 2010 and IBM SPSS.

**Results** After comparing all gathered data, it was found that the patients with APS and AMI had a more significant tendency to have C3 hypocomplementemia (p=0.006), thrombocytopenia (p=0.002), a lower ejection fraction on transthoracic echocardiography (p=0.04) and a more elevated number of abortions before acute myocardial infarction (p=0.03) in comparison to the controls.

**Conclusions** From our study it was found that APS is not rare in young adults with AMI. It should be always suspected in young patients with no cardiovascular risk factors and there may be a characteristic clinical and laboratory picture in patients with AMI, which may suggest the APS diagnosis.

**Acknowledgements** The authors declare no conflict of interest.

### P5: Recognizing the Disease, Treating the Patient: A Mixed-Method Evaluation of Care for the Antiphospholipid Syndrome (APS) in the Netherlands

**Background** Antiphospholipid syndrome and autoimmune diseases are chronic as well as complex and heterogeneous conditions with a high burden of disease. Differences in health care professionals’ knowledge and practice regarding APS are seen among countries, and within one country as well. Therefore, this study focuses on APS care in the Netherlands.

**Methods** A mixed-method approach was used with semi-structured interviews with medical specialists, patient focus groups and a cross-sectional, online patient survey. In order to examine differences in medical practice, medical records were reviewed retrospectively regarding clinical and laboratory manifestations, pharmacological treatment and management of disease in six hospitals throughout The Netherlands.

**Results** Fourteen interviewed medical specialists, fourteen focus group participants and 79 survey respondents participated in the study. 237 patients were included in medical record review. Only one-third of patients were diagnosed with APS within three months after entering specialist care. Diagnosis and management varied between centres and specialists. Almost 10% of triple positive patients did not receive any treatment at the time of medical record review. Major challenges according to specialists and patients were poor recognition of APS by health care professionals, fragmentation of care and lack of accessible, reliable patient education and psychosocial support.

**Conclusion** This study describes delayed diagnosis, variability in management strategies and a burden placed on patients to orchestrate their own care in APS care in The Netherlands. Of note, almost 10% of triple positive patients did not receive any treatment, despite this group of patients being at the highest risk of recurrent thrombosis.

**Acknowledgements** This work was supported by the Arthritis Research and Collaboration Hub (ARCH) Foundation.

### P6: Rituximab Efficacy in CAPS

**Background** Catastrophic antiphospholipid syndrome (CAPS) - thrombotic microangiopathy, characterized by involvement of systems and organs with formation of their insufficiency. Therapy of glucocorticoids and immunosuppressants with plasmapheresis and intravenous immunoglobulin demonstrates lack of effectivity. Currently, there are reports of rituximab effectiveness in APS and CAPS, but they are not numerous, especially CAPS.

**Methods** Assessment of the rituximab effectiveness in patients with resistant CAPS. We present the treatment results of two patients with CAPS, who were treated in our clinic.

**Results** Patient V. 21, was admitted in the early postpartum period. Diagnosis: Systemic lupus erythematosus, positivity for ANA: ds-DNA, Sm. Secondary antiphospholipid syndrome (positivity for β2-glycoprotein-1, cardiolipin, lupus anticoagulant), catastrophic APS with multiorgan failure: epilepsy, sopor, psychosis; acute renal injury, signs of acute respiratory distress syndrome and hypocoagulation. SLEDAI score was 56 points, GAPPS – 17 points. Pulse therapy with methylprednisolone, cyclophosphamide, plasmapheresis and intravenous immunoglobulin wasn’t effective enough. Rituximab course 375 mg/m² 1 time per week for 4 weeks was administered. Manifestations